Humoral immunity induced by mucosal and/or systemic SIV-specific vaccine platforms suggests novel combinatorial approaches for enhancing responses

Clinical Immunology

Volumn 153, Issue 2, 2014, Pages 308-322

  Vargas Inchaustegui, Diego A ^a   Tuero, Iskra ^a   Mohanram, Venkatramanan ^a   Musich, Thomas ^a   Pegu, Poonam ^a   Valentin, Antonio ^b   Sui, Yongjun ^a   Rosati, Margherita ^b   Bear, Jenifer ^b   Venzon, David J ^a   Kulkarni, Viraj ^b   Alicea, Candido ^b   Pilkington, Guy R ^b   Liyanage, Namal P M ^a   Demberg, Thorsten ^a   Gordon, Shari N ^a   Wang, Yichuan ^a   Hogg, Alison E ^a   Frey, Blake ^a   Patterson, L Jean ^a   DiPasquale, Janet ^a   Montefiori, David C ^c   Sardesai, Niranjan Y ^d   Reed, Steven G ^e   Berzofsky, Jay A ^a   Franchini, Genoveffa ^a   Felber, Barbara K ^b   Pavlakis, George N ^b   Robert Guroff, Marjorie ^a   more..

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d Inovio Pharmaceuticals Inc   (United States)

^e Infectious Diseases Research Institute   (United States)

Author keywords

Functional antibody activities; Memory B cells; Mucosal and systemic humoral immunity; Poxvirus , adenovirus , and DNA based vaccines; Simian immunodeficiency virus

Indexed keywords

CONDITIONALLY REPLICATING ADENOVIRUS; DNA VACCINE; GLYCOPROTEIN GP 120; NEUTRALIZING ANTIBODY; POXVIRUS VECTOR; RECOMBINANT VACCINE; SIMIAN IMMUNODEFICIENCY VIRUS VACCINE; VIRUS ENVELOPE PROTEIN;

ANIMAL EXPERIMENT; ANTIBODY BLOOD LEVEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; BONE MARROW CELL; CONTROLLED STUDY; DNA IMMUNIZATION; HUMORAL IMMUNITY; MEMORY CELL; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; RHESUS MONKEY; SYSTEMIC THERAPY; VACCINATION;

FUNCTIONAL ANTIBODY ACTIVITIES; MEMORY B CELLS; MUCOSAL AND SYSTEMIC HUMORAL IMMUNITY; POXVIRUS-, ADENOVIRUS-, AND DNA-BASED VACCINES; SIMIAN IMMUNODEFICIENCY VIRUS;

AIDS VACCINES; ANIMALS; ANTIBODIES, VIRAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; DRUG THERAPY, COMBINATION; ENZYME-LINKED IMMUNOSPOT ASSAY; GENE PRODUCTS, ENV; HUMANS; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MACACA MULATTA; SAIDS VACCINES; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; TIME FACTORS; VACCINATION; VACCINES, DNA; VACCINES, SUBUNIT;

EID: 84902682927     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2014.05.008     Document Type: Article

References (71)

1. Excler J.L., Tomaras G.D., Russell N.D. Novel directions in HIV-1 vaccines revealed from clinical trials. Curr. Opin. HIV AIDS 2013, 8:420-430.
2. Barouch D.H. Challenges in the development of an HIV-1 vaccine. Nature 2008, 455:613-619.
3. Rerks-Ngarm S., Pitisuttithum P., Nitayaphan S., Kaewkungwal J., Chiu J., Paris R., Premsri N., Namwat C., de Souza M., Adams E., Benenson M., Gurunathan S., Tartaglia J., McNeil J.G., Francis D.P., Stablein D., Birx D.L., Chunsuttiwat S., Khamboonruang C., Thongcharoen P., Robb M.L., Michael N.L., Kunasol P., Kim J.H. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 2009, 361:2209-2220.
4. Letvin N.L., Rao S.S., Montefiori D.C., Seaman M.S., Sun Y., Lim S.Y., Yeh W.W., Asmal M., Gelman R.S., Shen L., Whitney J.B., Seoighe C., Lacerda M., Keating S., Norris P.J., Hudgens M.G., Gilbert P.B., Buzby A.P., Mach L.V., Zhang J., Balachandran H., Shaw G.M., Schmidt S.D., Todd J.P., Dodson A., Mascola J.R., Nabel G.J. Immune and genetic correlates of vaccine protection against mucosal infection by SIV in monkeys. Sci. Transl. Med. 2011, 3. (81ra36).
5. Lai L., Kwa S.F., Kozlowski P.A., Montefiori D.C., Nolen T.L., Hudgens M.G., Johnson W.E., Ferrari G., Hirsch V.M., Felber B.K., Pavlakis G.N., Earl P.L., Moss B., Amara R.R., Robinson H.L. SIVmac239 MVA vaccine with and without a DNA prime, similar prevention of infection by a repeated dose SIVsmE660 challenge despite different immune responses. Vaccine 2012, 30:1737-1745.
6. Barouch D.H., Liu J., Li H., Maxfield L.F., Abbink P., Lynch D.M., Iampietro M.J., SanMiguel A., Seaman M.S., Ferrari G., Forthal D.N., Ourmanov I., Hirsch V.M., Carville A., Mansfield K.G., Stablein D., Pau M.G., Schuitemaker H., Sadoff J.C., Billings E.A., Rao M., Robb M.L., Kim J.H., Marovich M.A., Goudsmit J., Michael N.L. Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature 2012, 482:89-93.
7. Patel V., Jalah R., Kulkarni V., Valentin A., Rosati M., Alicea C., von Gegerfelt A., Huang W., Guan Y., Keele B.F., Bess J.W., Piatak M., Lifson J.D., Williams W.T., Shen X., Tomaras G.D., Amara R.R., Robinson H.L., Johnson W., Broderick K.E., Sardesai N.Y., Venzon D.J., Hirsch V.M., Felber B.K., Pavlakis G.N. DNA and virus particle vaccination protects against acquisition and confers control of viremia upon heterologous simian immunodeficiency virus challenge. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:2975-2980.
8. Bogers W.M., Davis D., Baak I., Kan E., Hofman S., Sun Y., Mortier D., Lian Y., Oostermeijer H., Fagrouch Z., Dubbes R., van der Maas M., Mooij P., Koopman G., Verschoor E., Langedijk J.P., Zhao J., Brocca-Cofano E., Robert-Guroff M., Srivastava I., Barnett S., Heeney J.L. Systemic neutralizing antibodies induced by long interval mucosally primed systemically boosted immunization correlate with protection from mucosal SHIV challenge. Virology 2008, 382:217-225.
9. Strbo N., Vaccari M., Pahwa S., Kolber M.A., Doster M.N., Fisher E., Gonzalez L., Stablein D., Franchini G., Podack E.R. Cutting edge: novel vaccination modality provides significant protection against mucosal infection by highly pathogenic simian immunodeficiency virus. J. Immunol. 2013, 190:2495-2499.
10. Hansen S.G., Ford J.C., Lewis M.S., Ventura A.B., Hughes C.M., Coyne-Johnson L., Whizin N., Oswald K., Shoemaker R., Swanson T., Legasse A.W., Chiuchiolo M.J., Parks C.L., Axthelm M.K., Nelson J.A., Jarvis M.A., Piatak M., Lifson J.D., Picker L.J. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 2011, 473:523-527.
11. Bomsel M., Tudor D., Drillet A.S., Alfsen A., Ganor Y., Roger M.G., Mouz N., Amacker M., Chalifour A., Diomede L., Devillier G., Cong Z., Wei Q., Gao H., Qin C., Yang G.B., Zurbriggen R., Lopalco L., Fleury S. Immunization with HIV-1 gp41 subunit virosomes induces mucosal antibodies protecting nonhuman primates against vaginal SHIV challenges. Immunity 2011, 34:269-280.
12. Barnett S.W., Burke B., Sun Y., Kan E., Legg H., Lian Y., Bost K., Zhou F., Goodsell A., Zur Megede J., Polo J., Donnelly J., Ulmer J., Otten G.R., Miller C.J., Vajdy M., Srivastava I.K. Antibody-mediated protection against mucosal simian-human immunodeficiency virus challenge of macaques immunized with alphavirus replicon particles and boosted with trimeric envelope glycoprotein in MF59 adjuvant. J. Virol. 2010, 84:5975-5985.
13. Mudd P.A., Martins M.A., Ericsen A.J., Tully D.C., Power K.A., Bean A.T., Piaskowski S.M., Duan L., Seese A., Gladden A.D., Weisgrau K.L., Furlott J.R., Kim Y.I., Veloso de Santana M.G., Rakasz E., Capuano S., Wilson N.A., Bonaldo M.C., Galler R., Allison D.B., Piatak M., Haase A.T., Lifson J.D., Allen T.M., Watkins D.I. Vaccine-induced CD8+ T cells control AIDS virus replication. Nature 2012, 491:129-133.
14. Hansen S.G., Sacha J.B., Hughes C.M., Ford J.C., Burwitz B.J., Scholz I., Gilbride R.M., Lewis M.S., Gilliam A.N., Ventura A.B., Malouli D., Xu G., Richards R., Whizin N., Reed J.S., Hammond K.B., Fischer M., Turner J.M., Legasse A.W., Axthelm M.K., Edlefsen P.T., Nelson J.A., Lifson J.D., Fruh K., Picker L.J. Cytomegalovirus vectors violate CD8+ T cell epitope recognition paradigms. Science (New York, N.Y.) 2013, 340:1237874.
15. Vargas-Inchaustegui D.A., Robert-Guroff M. Fc receptor-mediated immune responses: new tools but increased complexity in HIV prevention. Curr. HIV Res. 2013, 11:407-420.
16. Alpert M.D., Harvey J.D., Lauer W.A., Reeves R.K., Piatak M., Carville A., Mansfield K.G., Lifson J.D., Li W., Desrosiers R.C., Johnson R.P., Evans D.T. ADCC develops over time during persistent infection with live-attenuated SIV and is associated with complete protection against SIV(mac)251 challenge. PLoS Pathog. 2012, 8:e1002890.
17. Madhavi V., Kent S.J., Stratov I. HIV-specific antibody-dependent cellular cytotoxicity: a novel vaccine modality. Expert. Rev. Clin. Immunol. 2012, 8:767-774.
18. Alam S.M., Liao H.X., Tomaras G.D., Bonsignori M., Tsao C.Y., Hwang K.K., Chen H., Lloyd K.E., Bowman C., Sutherland L., Jeffries T.L., Kozink D.M., Stewart S., Anasti K., Jaeger F.H., Parks R., Yates N.L., Overman R.G., Sinangil F., Berman P.W., Pitisuttithum P., Kaewkungwal J., Nitayaphan S., Karasavva N., Rerks-Ngarm S., Kim J.H., Michael N.L., Zolla-Pazner S., Santra S., Letvin N.L., Harrison S.C., Haynes B.F. Antigenicity and immunogenicity of RV144 vaccine AIDSVAX clade E envelope immunogen is enhanced by a gp120 N-terminal deletion. J. Virol. 2013, 87:1554-1568.
19. Xiao P., Patterson L.J., Kuate S., Brocca-Cofano E., Thomas M.A., Venzon D., Zhao J., DiPasquale J., Fenizia C., Lee E.M., Kalisz I., Kalyanaraman V.S., Pal R., Montefiori D., Keele B.F., Robert-Guroff M. Replicating adenovirus-simian immunodeficiency virus (SIV) recombinant priming and envelope protein boosting elicits localized, mucosal IgA immunity in rhesus macaques correlated with delayed acquisition following a repeated low-dose rectal SIV(mac251) challenge. J. Virol. 2012, 86:4644-4657.
20. Haynes B.F., Gilbert P.B., McElrath M.J., Zolla-Pazner S., Tomaras G.D., Alam S.M., Evans D.T., Montefiori D.C., Karnasuta C., Sutthent R., Liao H.X., DeVico A.L., Lewis G.K., Williams C., Pinter A., Fong Y., Janes H., DeCamp A., Huang Y., Rao M., Billings E., Karasavvas N., Robb M.L., Ngauy V., de Souza M.S., Paris R., Ferrari G., Bailer R.T., Soderberg K.A., Andrews C., Berman P.W., Frahm N., De Rosa S.C., Alpert M.D., Yates N.L., Shen X., Koup R.A., Pitisuttithum P., Kaewkungwal J., Nitayaphan S., Rerks-Ngarm S., Michael N.L., Kim J.H. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N. Engl. J. Med. 2012, 366:1275-1286.
21. Karasavvas N., Billings E., Rao M., Williams C., Zolla-Pazner S., Bailer R.T., Koup R.A., Madnote S., Arworn D., Shen X., Tomaras G.D., Currier J.R., Jiang M., Magaret C., Andrews C., Gottardo R., Gilbert P., Cardozo T.J., Rerks-Ngarm S., Nitayaphan S., Pitisuttithum P., Kaewkungwal J., Paris R., Greene K., Gao H., Gurunathan S., Tartaglia J., Sinangil F., Korber B.T., Montefiori D.C., Mascola J.R., Robb M.L., Haynes B.F., Ngauy V., Michael N.L., Kim J.H., de Souza M.S. The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120. AIDS Res. Hum. Retrovir. 2012, 28:1444-1457.
22. Rolland M., Edlefsen P.T., Larsen B.B., Tovanabutra S., Sanders-Buell E., Hertz T., deCamp A.C., Carrico C., Menis S., Magaret C.A., Ahmed H., Juraska M., Chen L., Konopa P., Nariya S., Stoddard J.N., Wong K., Zhao H., Deng W., Maust B.S., Bose M., Howell S., Bates A., Lazzaro M., O'Sullivan A., Lei E., Bradfield A., Ibitamuno G., Assawadarachai V., O'Connell R.J., deSouza M.S., Nitayaphan S., Rerks-Ngarm S., Robb M.L., McLellan J.S., Georgiev I., Kwong P.D., Carlson J.M., Michael N.L., Schief W.R., Gilbert P.B., Mullins J.I., Kim J.H. Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. Nature 2012, 490:417-420.
23. Pal R., Venzon D., Santra S., Kalyanaraman V.S., Montefiori D.C., Hocker L., Hudacik L., Rose N., Nacsa J., Edghill-Smith Y., Moniuszko M., Hel Z., Belyakov I.M., Berzofsky J.A., Parks R.W., Markham P.D., Letvin N.L., Tartaglia J., Franchini G. Systemic immunization with an ALVAC-HIV-1/protein boost vaccine strategy protects rhesus macaques from CD4+ T-cell loss and reduces both systemic and mucosal simian-human immunodeficiency virus SHIVKU2 RNA levels. J. Virol. 2006, 80:3732-3742.
24. Pal R., Venzon D., Letvin N.L., Santra S., Montefiori D.C., Miller N.R., Tryniszewska E., Lewis M.G., VanCott T.C., Hirsch V., Woodward R., Gibson A., Grace M., Dobratz E., Markham P.D., Hel Z., Nacsa J., Klein M., Tartaglia J., Franchini G. ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency. J. Virol. 2002, 76:292-302.
25. Hel Z., Nacsa J., Tsai W.P., Thornton A., Giuliani L., Tartaglia J., Franchini G. Equivalent immunogenicity of the highly attenuated poxvirus-based ALVAC-SIV and NYVAC-SIV vaccine candidates in SIVmac251-infected macaques. Virology 2002, 304:125-134.
26. Pegu P., Vaccari M., Gordon S., Keele B.F., Doster M., Guan Y., Ferrari G., Pal R., Ferrari M.G., Whitney S., Hudacik L., Billings E., Rao M., Montefiori D., Tomaras G., Alam S.M., Fenizia C., Lifson J.D., Stablein D., Tartaglia J., Michael N., Kim J., Venzon D., Franchini G. Antibodies with high avidity to the gp120 envelope protein in protection from simian immunodeficiency virus SIV(mac251) acquisition in an immunization regimen that mimics the RV-144 Thai trial. J. Virol. 2013, 87:1708-1719.
27. Vaccari M., Keele B.F., Bosinger S.E., Doster M.N., Ma Z.M., Pollara J., Hryniewicz A., Ferrari G., Guan Y., Forthal D.N., Venzon D., Fenizia C., Morgan T., Montefiori D., Lifson J.D., Miller C.J., Silvestri G., Rosati M., Felber B.K., Pavlakis G.N., Tartaglia J., Franchini G. Protection afforded by an HIV vaccine candidate in macaques depends on the dose of SIVmac251 at challenge exposure. J. Virol. 2013, 87:3538-3548.
28. Jalah R., Patel V., Kulkarni V., Rosati M., Alicea C., Ganneru B., von Gegerfelt A., Huang W., Guan Y., Broderick K.E., Sardesai N.Y., LaBranche C., Montefiori D.C., Pavlakis G.N., Felber B.K. IL-12 DNA as molecular vaccine adjuvant increases the cytotoxic T cell responses and breadth of humoral immune responses in SIV DNA vaccinated macaques. Hum. Vaccin. Immunother. 2012, 8:1620-1629.
29. Rosati M., Bergamaschi C., Valentin A., Kulkarni V., Jalah R., Alicea C., Patel V., von Gegerfelt A.S., Montefiori D.C., Venzon D.J., Khan A.S., Draghia-Akli R., Van Rompay K.K., Felber B.K., Pavlakis G.N. DNA vaccination in rhesus macaques induces potent immune responses and decreases acute and chronic viremia after SIVmac251 challenge. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:15831-15836.
30. Rosati M., Valentin A., Jalah R., Patel V., von Gegerfelt A., Bergamaschi C., Alicea C., Weiss D., Treece J., Pal R., Markham P.D., Marques E.T., August J.T., Khan A., Draghia-Akli R., Felber B.K., Pavlakis G.N. Increased immune responses in rhesus macaques by DNA vaccination combined with electroporation. Vaccine 2008, 26:5223-5229.
31. Kulkarni V., Rosati M., Valentin A., Ganneru B., Singh A.K., Yan J., Rolland M., Alicea C., Beach R.K., Zhang G.M., Le Gall S., Broderick K.E., Sardesai N.Y., Heckerman D., Mothe B., Brander C., Weiner D.B., Mullins J.I., Pavlakis G.N., Felber B.K. HIV-1 p24(gag) derived conserved element DNA vaccine increases the breadth of immune response in mice. PLoS One 2013, 8:e60245.
32. Li J., Valentin A., Kulkarni V., Rosati M., Beach R.K., Alicea C., Hannaman D., Reed S.G., Felber B.K., Pavlakis G.N. HIV/SIV DNA vaccine combined with protein in a co-immunization protocol elicits highest humoral responses to envelope in mice and macaques. Vaccine 2013, 31:3747-3755.
33. Patel V., Valentin A., Kulkarni V., Rosati M., Bergamaschi C., Jalah R., Alicea C., Minang J.T., Trivett M.T., Ohlen C., Zhao J., Robert-Guroff M., Khan A.S., Draghia-Akli R., Felber B.K., Pavlakis G.N. Long-lasting humoral and cellular immune responses and mucosal dissemination after intramuscular DNA immunization. Vaccine 2010, 28:4827-4836.
34. Patterson L.J., Robert-Guroff M. Replicating adenovirus vector prime/protein boost strategies for HIV vaccine development. Expert. Opin. Biol. Ther. 2008, 8:1347-1363.
35. Lubeck M.D., Natuk R., Myagkikh M., Kalyan N., Aldrich K., Sinangil F., Alipanah S., Murthy S.C., Chanda P.K., Nigida S.M., Markham P.D., Zolla-Pazner S., Steimer K., Wade M., Reitz M.S., Arthur L.O., Mizutani S., Davis A., Hung P.P., Gallo R.C., Eichberg J., Robert-Guroff M. Long-term protection of chimpanzees against high-dose HIV-1 challenge induced by immunization. Nat. Med. 1997, 3:651-658.
36. Malkevitch N.V., Patterson L.J., Aldrich M.K., Wu Y., Venzon D., Florese R.H., Kalyanaraman V.S., Pal R., Lee E.M., Zhao J., Cristillo A., Robert-Guroff M. Durable protection of rhesus macaques immunized with a replicating adenovirus-SIV multigene prime/protein boost vaccine regimen against a second SIVmac251 rectal challenge: role of SIV-specific CD8+ T cell responses. Virology 2006, 353:83-98.
37. Demberg T., Florese R.H., Heath M.J., Larsen K., Kalisz I., Kalyanaraman V.S., Lee E.M., Pal R., Venzon D., Grant R., Patterson L.J., Korioth-Schmitz B., Buzby A., Dombagoda D., Montefiori D.C., Letvin N.L., Cafaro A., Ensoli B., Robert-Guroff M. A replication-competent adenovirus-human immunodeficiency virus (Ad-HIV) tat and Ad-HIV env priming/Tat and envelope protein boosting regimen elicits enhanced protective efficacy against simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques. J. Virol. 2007, 81:3414-3427.
38. Sui Y., Gagnon S., Dzutsev A., Zhu Q., Yu H., Hogg A., Wang Y., Xia Z., Belyakov I.M., Venzon D., Klinman D., Strober W., Kelsall B., Franchini G., Berzofsky J.A. TLR agonists and/or IL-15 adjuvanted mucosal SIV vaccine reduced gut CD4(+) memory T cell loss in SIVmac251-challenged rhesus macaques. Vaccine 2011, 30:59-68.
39. Belyakov I.M., Kuznetsov V.A., Kelsall B., Klinman D., Moniuszko M., Lemon M., Markham P.D., Pal R., Clements J.D., Lewis M.G., Strober W., Franchini G., Berzofsky J.A. Impact of vaccine-induced mucosal high-avidity CD8+ CTLs in delay of AIDS viral dissemination from mucosa. Blood 2006, 107:3258-3264.
40. Belyakov I.M., Hel Z., Kelsall B., Kuznetsov V.A., Ahlers J.D., Nacsa J., Watkins D.I., Allen T.M., Sette A., Altman J., Woodward R., Markham P.D., Clements J.D., Franchini G., Strober W., Berzofsky J.A. Mucosal AIDS vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macaques. Nat. Med. 2001, 7:1320-1326.
41. Sui Y., Zhu Q., Gagnon S., Dzutsev A., Terabe M., Vaccari M., Venzon D., Klinman D., Strober W., Kelsall B., Franchini G., Belyakov I.M., Berzofsky J.A. Innate and adaptive immune correlates of vaccine and adjuvant-induced control of mucosal transmission of SIV in macaques. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:9843-9848.
42. Smith D.H., Winters-Digiacinto P., Mitiku M., O'Rourke S., Sinangil F., Wrin T., Montefiori D.C., Berman P.W. Comparative immunogenicity of HIV-1 clade C envelope proteins for prime/boost studies. PLoS One 2010, 5:e12076.
43. Lasky L.A., Groopman J.E., Fennie C.W., Benz P.M., Capon D.J., Dowbenko D.J., Nakamura G.R., Nunes W.M., Renz M.E., Berman P.W. Neutralization of the AIDS retrovirus by antibodies to a recombinant envelope glycoprotein. Science 1986, 233:209-212.
44. Keele B.F., Li H., Learn G.H., Hraber P., Giorgi E.E., Grayson T., Sun C., Chen Y., Yeh W.W., Letvin N.L., Mascola J.R., Nabel G.J., Haynes B.F., Bhattacharya T., Perelson A.S., Korber B.T., Hahn B.H., Shaw G.M. Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1. J. Exp. Med. 2009, 206:1117-1134.
45. Kulkarni V., Rosati M., Bear J., Pilkington G.R., Jalah R., Bergamaschi C., Singh A.K., Alicea C., Chowdhury B., Zhang G.M., Kim E.Y., Wolinsky S.M., Huang W., Guan Y., Labranche C., Montefiori D.C., Broderick K.E., Sardesai N.Y., Valentin A., Felber B.K., Pavlakis G.N. Comparison of intradermal and intramuscular delivery followed in vivo electroporation of SIV Env DNA in macaques. Hum. Vaccin. Immunother. 2013, 9:2081-2094.
46. Coler R.N., Bertholet S., Moutaftsi M., Guderian J.A., Windish H.P., Baldwin S.L., Laughlin E.M., Duthie M.S., Fox C.B., Carter D., Friede M., Vedvick T.S., Reed S.G. Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant. PLoS One 2011, 6:e16333.
47. Demberg T., Brocca-Cofano E., Xiao P., Venzon D., Vargas-Inchaustegui D., Lee E.M., Kalisz I., Kalyanaraman V.S., Dipasquale J., McKinnon K., Robert-Guroff M. Dynamics of memory B-cell populations in blood, lymph nodes, and bone marrow during antiretroviral therapy and envelope boosting in simian immunodeficiency virus SIVmac251-infected rhesus macaques. J. Virol. 2012, 86:12591-12604.
48. Vargas-Inchaustegui D.A., Demberg T., Robert-Guroff M. A CD8alpha(-) subpopulation of macaque circulatory natural killer cells can mediate both antibody-dependent and antibody-independent cytotoxic activities. Immunology 2011, 134:326-340.
49. Patterson L.J., Daltabuit-Test M., Xiao P., Zhao J., Hu W., Wille-Reece U., Brocca-Cofano E., Kalyanaraman V.S., Kalisz I., Whitney S., Lee E.M., Pal R., Montefiori D.C., Dandekar S., Seder R., Roederer M., Wiseman R.W., Hirsch V., Robert-Guroff M. Rapid SIV Env-specific mucosal and serum antibody induction augments cellular immunity in protecting immunized, elite-controller macaques against high dose heterologous SIV challenge. Virology 2011, 411:87-102.
50. Demberg T., Brocca-Cofano E., Kuate S., Aladi S., Vargas-Inchaustegui D.A., Venzon D., Kalisz I., Kalyanaraman V.S., Lee E.M., Pal R., Dipasquale J., Ruprecht R.M., Montefiori D.C., Srivastava I., Barnett S.W., Robert-Guroff M. Impact of antibody quality and anamnestic response on viremia control post-challenge in a combined Tat/Env vaccine regimen in rhesus macaques. Virology 2013, 440:210-221.
51. Montefiori D.C. Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays. Curr. Protoc. Immunol. Chapter 12 2005, 12.11.1-12.11.17. (Unit 12 11).
52. Ackerman M.E., Moldt B., Wyatt R.T., Dugast A.S., McAndrew E., Tsoukas S., Jost S., Berger C.T., Sciaranghella G., Liu Q., Irvine D.J., Burton D.R., Alter G. A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples. J. Immunol. Methods 2011, 366:8-19.
53. Gomez-Roman V.R., Florese R.H., Patterson L.J., Peng B., Venzon D., Aldrich K., Robert-Guroff M. A simplified method for the rapid fluorometric assessment of antibody-dependent cell-mediated cytotoxicity. J. Immunol. Methods 2006, 308:53-67.
54. Brocca-Cofano E., McKinnon K., Demberg T., Venzon D., Hidajat R., Xiao P., Daltabuit-Test M., Patterson L.J., Robert-Guroff M. Vaccine-elicited SIV and HIV envelope-specific IgA and IgG memory B cells in rhesus macaque peripheral blood correlate with functional antibody responses and reduced viremia. Vaccine 2011, 29:3310-3319.
55. Bertley F.M., Kozlowski P.A., Wang S.W., Chappelle J., Patel J., Sonuyi O., Mazzara G., Montefiori D., Carville A., Mansfield K.G., Aldovini A. Control of simian/human immunodeficiency virus viremia and disease progression after IL-2-augmented DNA-modified vaccinia virus Ankara nasal vaccination in nonhuman primates. J. Immunol. 2004, 172:3745-3757.
56. Manrique M., Kozlowski P.A., Wang S.W., Wilson R.L., Micewicz E., Montefiori D.C., Mansfield K.G., Carville A., Aldovini A. Nasal DNA-MVA SIV vaccination provides more significant protection from progression to AIDS than a similar intramuscular vaccination. Mucosal Immunol. 2009, 2:536-550.
57. Lanzavecchia A., Sallusto F. Human B cell memory. Curr. Opin. Immunol. 2009, 21:298-304.
58. Piot P., Quinn T.C. Response to the AIDS pandemic-a global health model. N. Engl. J. Med. 2013, 368:2210-2218.
59. Lakhashe S.K., Silvestri G., Ruprecht R.M. No acquisition: a new ambition for HIV vaccine development?. Curr. Opin. Virol. 2011, 1:246-253.
60. Jaworski J.P., Krebs S.J., Trovato M., Kovarik D.N., Brower Z., Sutton W.F., Waagmeester G., Sartorius R., D'Apice L., Caivano A., Doria-Rose N.A., Malherbe D., Montefiori D.C., Barnett S., De Berardinis P., Haigwood N.L. Co-immunization with multimeric scaffolds and DNA rapidly induces potent autologous HIV-1 neutralizing antibodies and CD8+ T cells. PLoS One 2012, 7:e31464.
61. Okada T., Cyster J.G. B cell migration and interactions in the early phase of antibody responses. Curr. Opin. Immunol. 2006, 18:278-285.
62. Zhang Q., Iida R., Shimazu T., Kincade P.W. Replenishing B lymphocytes in health and disease. Curr. Opin. Immunol. 2012, 24:196-203.
63. Patterson L.J., Kuate S., Daltabuit-Test M., Li Q., Xiao P., McKinnon K., DiPasquale J., Cristillo A., Venzon D., Haase A., Robert-Guroff M. Replicating adenovirus-simian immunodeficiency virus (SIV) vectors efficiently prime SIV-specific systemic and mucosal immune responses by targeting myeloid dendritic cells and persisting in rectal macrophages, regardless of immunization route. Clin. Vaccine Immunol. 2012, 19:629-637.
64. Fagarasan S., Honjo T. Intestinal IgA synthesis: regulation of front-line body defences. Nat. Rev. Immunol. 2003, 3:63-72.
65. Bomsel M., Heyman M., Hocini H., Lagaye S., Belec L., Dupont C., Desgranges C. Intracellular neutralization of HIV transcytosis across tight epithelial barriers by anti-HIV envelope protein dIgA or IgM. Immunity 1998, 9:277-287.
66. Forthal D., Hope T.J., Alter G. New paradigms for functional HIV-specific nonneutralizing antibodies. Curr. Opin. HIV AIDS 2013, 8:392-400.
67. Sutherland D.B., Fagarasan S. IgA synthesis: a form of functional immune adaptation extending beyond gut. Curr. Opin. Immunol. 2012, 24:261-268.
68. Wu X., Jackson S. Plasma and salivary IgG subclasses in HIV type 1 infection: evidence of both transudation and local synthesis of IgG in parotid saliva. AIDS Res. Hum. Retrovir. 2000, 16:1423-1431.
69. McCoy L.E., Weiss R.A. Neutralizing antibodies to HIV-1 induced by immunization. J. Exp. Med. 2013, 210:209-223.
70. Robinson H.L. Non-neutralizing antibodies in prevention of HIV infection. Expert. Opin. Biol. Ther. 2013, 13:197-207.
71. Tomaras G.D., Ferrari G., Shen X., Alam S.M., Liao H.X., Pollara J., Bonsignori M., Moody M.A., Fong Y., Chen X., Poling B., Nicholson C.O., Zhang R., Lu X., Parks R., Kaewkungwal J., Nitayaphan S., Pitisuttithum P., Rerks-Ngarm S., Gilbert P.B., Kim J.H., Michael N.L., Montefiori D.C., Haynes B.F. Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG. PNAS USA 2013, 110:9019-9024.